• Income Statement
• Balance Sheet
• Cash Flow
• Ratios
• Market Data
• Valuation

	BIOREGENX, INC. (FDIT)
	Q2-CY2026	Q1-CY2026	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014
Balance Sheet Date			2025-Dec-31	2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31
Fiscal Period			Q4-FY2025	Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023
Total Revenue			385,641$	507,755$	445,970$	515,147$	460,489$	596,037$	734,032$	549,548$	678,008$	794,544$	863,278$	1,075,585$
QoQ%			(24.05%)	13.85%	(13.43%)	11.87%	(22.74%)	(18.80%)	33.57%	(18.95%)	(14.67%)	(7.96%)	(19.74%)
YoY%			(16.25%)	(14.81%)	(39.24%)	(6.26%)	(32.08%)	(24.98%)	(14.97%)	(48.91%)
Cost Of Revenue			66,866$	81,358$	93,514$	109,116$	137,752$	114,389$	264,154$	165,390$	299,983$	223,343$	264,967$	311,694$
Gross Profit			318,775$	426,397$	352,456$	406,031$	322,737$	481,648$	469,878$	384,158$	378,025$	571,201$	598,311$	763,891$
Gross Margin			82.66%	83.98%	79.03%	78.82%	70.09%	80.81%	64.01%	69.90%	55.76%	71.89%	69.31%	71.02%
Operating Expenses			1,254,433$	434,856$	459,715$	598,646$	18,639,552$	808,955$	1,509,675$	3,463,594$	589,580$	3,039,754$	1,142,930$	947,997$
Operating Income			(935,658$)	(8,459$)	(107,259$)	(192,615$)	(18,316,815$)	(327,307$)	(1,039,797$)	(3,079,436$)	(211,555$)	(2,468,553$)	(544,619$)	(184,106$)
Operating Margin			(242.62%)	(1.67%)	(24.05%)	(37.39%)	(3,977.69%)	(54.91%)	(141.66%)	(560.36%)	(31.20%)	(310.69%)	(63.09%)	(17.12%)
Interest Income
Interest Expenses			82,147$	72,106$	71,086$		83,756$	67,553$	66,331$	0$			0$	0$
Income Before Tax			(1,017,805$)	(80,565$)	(178,345$)	(266,854$)	(18,400,571$)	(394,860$)	(1,106,128$)	(704,806$)	(256,748$)	(2,519,035$)	(594,461$)	(229,838$)
Tax Expenses
Net Income			(1,017,805$)	(80,565$)	(178,345$)	(266,854$)	(18,400,571$)	(394,860$)	(1,106,128$)	(704,806$)	(256,748$)	(2,519,035$)	(594,461$)	(229,838$)
Profit Margin			(263.93%)	(15.87%)	(39.99%)	(51.80%)	(3,995.88%)	(66.25%)	(150.69%)	(128.25%)	(37.87%)	(317.04%)	(68.86%)	(21.37%)
TTM			(83.23%)	(980.96%)	(953.62%)	(874.72%)	(880.57%)	(96.28%)	(166.42%)	(141.23%)	(105.53%)
Earnings to Minority										2,447,652$
Earnings to Common Shareholders			(1,017,805$)	(80,565$)	(178,345$)	(266,854$)	(18,400,571$)	(394,860$)	(1,106,128$)	(3,152,458$)	(256,748$)	(2,519,035$)	(594,461$)	(229,838$)
QoQ%			(1,163.33%)	54.83%	33.17%	98.55%	(4,560.02%)	64.30%	64.91%	(1,127.84%)	89.81%	(323.75%)	(158.64%)
YoY%			94.47%	79.60%	83.88%	91.54%	(7,066.78%)	84.33%	(86.07%)	(1,271.60%)
Earnings Per Share, Basic			0.00$	0.00$	0.00$	0.00$	(0.02$)	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$
Earnings Per Share, Diluted			0.00$	0.00$	0.00$	0.00$	(0.02$)	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$
Unlevered FCF Per Share, Basic			0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$
Unlevered FCF Per Share, Diluted			0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$	0.00$
Average Shares, Basic			961,767,430	960,873,144	959,205,422	956,994,100	968,804,680	956,530,100	956,530,100	767,597,772	553,926,765	621,921,192	764,300,475	618,972,656
Average Shares, Diluted			961,767,430	960,873,144	959,205,422	956,994,100	968,804,680	956,530,100	956,530,100	767,597,772	553,926,765	621,921,192	764,300,475	618,972,656
EBIT			(935,658$)	(8,459$)	(107,259$)	(266,854$)	(18,316,815$)	(327,307$)	(1,039,797$)	(704,806$)	(256,748$)	(2,519,035$)	(594,461$)	(229,838$)
EBITDA			(935,658$)	3,917$	(69,882$)	(254,477$)	(16,120,401$)	(314,930$)	(1,032,155$)	(204,276$)	(256,749$)	(2,517,842$)	(593,267$)	(228,644$)

Copy Table ✓